Key points from article :
FOXO Technologies announced the licence of epigenetic clocks, PhenoAge and GrimAge, for use in the prediction of human mortality in the life insurance industry.
In addition to the Epigenetic Mortality Predictor, FOXO gives the exclusive usage of epigenetic clocks for the financial services industry.
Uses AI, epigenetics and cutting-edge bioinformatics tools to develop and commercialise epigenetic biomarkers of health and aging.
Broad application for its proprietary biomarker technology for insurers, health researchers and life science companies.
A competitive advantage in its mission to modernise life insurance through FOXO LIFE.
“Epigenetic clocks developed by Dr Steve Horvath are the gold standard in understanding biological aging,” - Jon Sabes, CEO of FOXO.
Dr Horvath’s research has shown that anti-aging longevity research can better focus on...stabilising epigenetic changes.
FOXO announced its first external funding of $10 million, bringing the total to $40 million of funding secured to date.
